Charlotte Pahl

Director/Miembro de la Junta en Reponex Pharmaceuticals A/S .

Fortuna: 129 741 $ al 30/04/2024

Health Technology

Perfil

Charlotte Pahl currently works as a Director at Reponex Pharmaceuticals A.

Empresa	Fecha	Número de acciones	Valoración	Fecha de valoración
PHARMA EQUITY GROUP A/S CLASS A 0.36%	31/12/2023	3 694 210 ( 0.36% )	129 741 $	30/04/2024

Empresas	Cargo	Inicio
Reponex Pharmaceuticals A/S Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million.	Director/Miembro de la Junta	-

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas privadas	1
Reponex Pharmaceuticals A/S Reponex Pharmaceuticals A/S BiotechnologyHealth Technology Part of Pharma Equity Group A/S, Reponex Pharmaceuticals A/S operates as a Danish clinical stage biopharmaceutical company. The company is based in Hørsholm, Denmark. The company was founded in 2006. The CEO is Soren Nielsen. Reponex Pharmaceuticals was acquired by Pharma Equity Group A/S on March 24, 2023 for $109.83 million.	Health Technology

Empresas privadas

Health Technology